Archive - May 2023
-
Plausibility hurdle in the UK shifted up a notch, as invalidity of BMS patent confirmed by Court of Appeal
22 May 2023Read more >Summary The UK Court of Appeal (CoA) confirmed the invalidity of Bristol-Myers Squibb (BMS)’s apixaban patent on 4 May 2023.1 The appeal decision centred on the question of plausibility and is the first UK decision to consider plausibility since the EPO Enlarged Board of Appeal’s decision G2/21. The CoA held that BMS had not presented […]
